Abstract
Fas (CD95) ligand (FasL) has the ability to induce apoptosis in Fas-expressing glioma cells by binding to Fas. Several molecular species have been designed to be soluble Fas ligands for therapeutic purposes. We successfully constructed a chimeric soluble FasL by fusing an isoleucine zipper motif for self-oligomerization and a FLAG sequence to the extracellular domain of the human Fas ligand (FIZ-shFasL). The cytotoxic effect of FIZ-shFasL on Jurkat cells was equivalent to that of membrane-bound FasL and approximately 10-fold stronger than that of agonistic anti-Fas antibody (CH-11). Flow cytometric analysis demonstrated that the differential Fas expression of human brain tumor cell lines partially correlated with levels of apoptosis through FIZ-shFasL. The upper limit of FIZ-shFasL for safe systemic administration to rat is estimated as below 2 microg/ml in plasma concentration. FIZ-shFasL could be applicable as a therapeutic agent for cancer.
Publication types
-
Evaluation Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / toxicity
-
Apoptosis / drug effects*
-
Body Weight / drug effects
-
Cell Line, Tumor / drug effects
-
Cell Line, Tumor / pathology
-
Cell Survival / drug effects
-
Fas Ligand Protein
-
Female
-
Humans
-
Isoleucine / administration & dosage*
-
Isoleucine / chemistry
-
Isoleucine / genetics
-
Isoleucine / toxicity*
-
Jurkat Cells
-
Leucine Zippers
-
Membrane Glycoproteins / administration & dosage*
-
Membrane Glycoproteins / chemistry
-
Membrane Glycoproteins / genetics
-
Membrane Glycoproteins / toxicity
-
Organ Size / drug effects
-
Rats
-
Rats, Wistar
-
Recombinant Fusion Proteins / administration & dosage*
-
Recombinant Fusion Proteins / toxicity*
-
Solubility
-
fas Receptor / metabolism*
Substances
-
Antineoplastic Agents
-
FASLG protein, human
-
Fas Ligand Protein
-
Faslg protein, rat
-
Membrane Glycoproteins
-
Recombinant Fusion Proteins
-
fas Receptor
-
Isoleucine